Latest News & Features
Big Pharma
Being both an innovator and a generic drug company gives Teva a good view of the patent litigation landscape, as Galit Gonen, general counsel, Teva Europe, tells LSIPR. 27 October 2015
Asia-Pacific
Pharmaceutical trademark owners in Australia should carefully select and register their marks to minimise potential problems associated with including INNs or INN stems, as Geordie Oldfield of Dennemeyer explains. 27 October 2015
Americas
The future of Brazil’s technological innovation centres, which bring together public and private sector parties to develop mainly life sciences technology, looks bright. Gabriel Di Blasi and Felipe Barros Oquendo of Di Blasi, Parente & Associados report 27 October 2015
Big Pharma
UK court decisions in Warner-Lambert v Actavis seek to define second medical use patent rights, and the recent full trial ruling provides some early guidance on the ‘reasonable foreseeability’ test concerning patent use, says Steve Smith of Potter Clarkson. 27 October 2015
Asia
Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further. 27 October 2015
Americas
Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key
provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe. 27 October 2015
Americas
US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases. 26 October 2015
Americas
Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases. 23 October 2015
Americas
Very few members of Congress are informed about the trajectory of section 101 and instead lawmakers are looking at ‘trolls’ and other patent issues, according to a counsel at the Biotechnology Industry Organization. 23 October 2015
Americas
Ariosa Diagnostics has urged the US Court of Appeals for the Federal Circuit to reject Sequenom’s en banc request, stating that behind its “sky is falling” rhetoric is really a demand for courts to revise the US Supreme Court’s two-part test in determining the eligibility of a patent. 22 October 2015